Skip to navigation Skip to content



​Results Announced from Phase 2 Myelin Repair Trial in Relapsing MS

June 7, 2016

Biogen announced results from a Phase 2 clinical trial of anti-LINGO (opicinumab), an approach to repair myelin, the nerve-insulating casing damaged in multiple sclerosis. According to the company’s press release, the trial did not meet its primary endpoint, which was improvement in measures of physical function (including walking, upper limb coordination), cognitive function, or disability. The trial involved 418 people with relapsing MS (including relapsing-remitting and secondary-progressive MS) who were taking interferon beta-1a (Avonex) plus one of several doses of intravenous opicinumab or placebo for 72 weeks.
The company is still evaluating results from the extensive testing and monitoring that occurred during the trial to help determine next steps for testing opicinumab in the future. The findings are likely to inform and enhance the design of future trials of myelin repair strategies in people with MS.
Additional myelin repair strategies for MS are undergoing laboratory research and clinical trials, including a trial recruiting people nationwide who are experiencing a relapse.
Another Phase 2 clinical trial of anti-LINGO was positive. It involved people who had experienced optic neuritis, which is often the first clinical episode of MS. Read more 
Read more about the trial results in Genetic Engineering & Biotechnology News
Read more about research to repair the nervous system in MS

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.